Global Menopause Drugs Market

Menopause Drugs Comprehensive Study by End-users (Hospitals & Clinics, Academia & Research), Symptoms (Hot flashes, Formication, Migraine, Fatigue, Anxiety, Irritability, Mood Swings, Others), Treatment (Hormonal Treatment, Non-hormonal Treatment) Players and Region - Global Market Outlook to 2030

Menopause Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Menopause Drugs
Menopause is an herbal technique with redress that focal point on symptomatic relief. Vaginal dryness is dealt with topical lubricants or oestrogen. Medications can decrease the severity and frequency of hot flushes. Estrogen remedy is the most high quality cure alternative for relieving menopausal warm flashes. Menopause happens when you have long past 12 consecutive months barring a menstrual period. Changing degrees of estrogen and progesterone, two lady hormones made in the ovaries, lead to signs and symptoms like warm flashes and vaginal dryness. Menopause is an herbal section of ageing and marks the give up of the lady reproductive years.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Menopause Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novo Nordisk A/S (Denmark), Pfizer Inc. (United States), Allergan (Ireland), Eli Lily and Company (United States), Emcure Pharmaceuticals Ltd (India), Novartis AG (Switzerland), Cipla Inc. (India) and Teva Pharmaceuticals (Israel) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Merck & Co. Inc. (United States), Abbott Laboratories (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Menopause Drugs market by and Region.



On the basis of geography, the market of Menopause Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-users, the sub-segment i.e. Hospitals & Clinics will boost the Menopause Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Hot flashes will boost the Menopause Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment , the sub-segment i.e. Hormonal Treatment will boost the Menopause Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Investments are being made in Extensive R&D activities to Launch Novel Drugs, which helps bolster the Menopause Treatment

Market Growth Drivers:
Effective Treatment for Menopause Symptoms has become extremely necessary in Recent Years and Nowadays are Increasingly Falling Prey to the Changing Lifestyle that leaves no Room for Relaxation, Leaving them deprived of Sleep and hence, Frustrated

Challenges:
Lack of Advanced Healthcare Infrastructure in Developing Countries

Restraints:
High Cost of Treatment

Opportunities:
Herbal Treatment for Menopause Turns Out to be a Major

Market Leaders and their expansionary development strategies
In August 2020, Bayer bolstered its women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and its investigational treatment for menopause.
In 2020, Bayer acquired KaNDy Therapeutics (UK), developer of treatment for menopausal symptoms at more than USD 800 million, in a bid to add the latter’s menopausal drug to its burgeoning pipeline of women’s health segment. Bayer is on track to bolster its women’s health segment via strategic acquisitions and collaborations.


Key Target Audience
Menopause Drugs Manufacturers, Menopause Drugs Distributors and Suppliers, Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By End-users
  • Hospitals & Clinics
  • Academia & Research

By Symptoms
  • Hot flashes
  • Formication
  • Migraine
  • Fatigue
  • Anxiety
  • Irritability
  • Mood Swings
  • Others

By Treatment
  • Hormonal Treatment
  • Non-hormonal Treatment

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Effective Treatment for Menopause Symptoms has become extremely necessary in Recent Years
      • 3.2.2. Nowadays are Increasingly Falling Prey to the Changing Lifestyle that leaves no Room for Relaxation, Leaving them deprived of Sleep and hence, Frustrated
    • 3.3. Market Challenges
      • 3.3.1. Lack of Advanced Healthcare Infrastructure in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Investments are being made in Extensive R&D activities to Launch Novel Drugs, which helps bolster the Menopause Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Menopause Drugs, by End-users, Symptoms, Treatment and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Menopause Drugs (Value)
      • 5.2.1. Global Menopause Drugs by: End-users (Value)
        • 5.2.1.1. Hospitals & Clinics
        • 5.2.1.2. Academia & Research
      • 5.2.2. Global Menopause Drugs by: Symptoms (Value)
        • 5.2.2.1. Hot flashes
        • 5.2.2.2. Formication
        • 5.2.2.3. Migraine
        • 5.2.2.4. Fatigue
        • 5.2.2.5. Anxiety
        • 5.2.2.6. Irritability
        • 5.2.2.7. Mood Swings
        • 5.2.2.8. Others
      • 5.2.3. Global Menopause Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Menopause Drugs (Volume)
      • 5.3.1. Global Menopause Drugs by: End-users (Volume)
        • 5.3.1.1. Hospitals & Clinics
        • 5.3.1.2. Academia & Research
      • 5.3.2. Global Menopause Drugs by: Symptoms (Volume)
        • 5.3.2.1. Hot flashes
        • 5.3.2.2. Formication
        • 5.3.2.3. Migraine
        • 5.3.2.4. Fatigue
        • 5.3.2.5. Anxiety
        • 5.3.2.6. Irritability
        • 5.3.2.7. Mood Swings
        • 5.3.2.8. Others
      • 5.3.3. Global Menopause Drugs Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Menopause Drugs (Price)
  • 6. Menopause Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novo Nordisk A/S (Denmark)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lily and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Emcure Pharmaceuticals Ltd (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cipla Inc. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceuticals (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Menopause Drugs Sale, by End-users, Symptoms, Treatment and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Menopause Drugs (Value)
      • 7.2.1. Global Menopause Drugs by: End-users (Value)
        • 7.2.1.1. Hospitals & Clinics
        • 7.2.1.2. Academia & Research
      • 7.2.2. Global Menopause Drugs by: Symptoms (Value)
        • 7.2.2.1. Hot flashes
        • 7.2.2.2. Formication
        • 7.2.2.3. Migraine
        • 7.2.2.4. Fatigue
        • 7.2.2.5. Anxiety
        • 7.2.2.6. Irritability
        • 7.2.2.7. Mood Swings
        • 7.2.2.8. Others
      • 7.2.3. Global Menopause Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Menopause Drugs (Volume)
      • 7.3.1. Global Menopause Drugs by: End-users (Volume)
        • 7.3.1.1. Hospitals & Clinics
        • 7.3.1.2. Academia & Research
      • 7.3.2. Global Menopause Drugs by: Symptoms (Volume)
        • 7.3.2.1. Hot flashes
        • 7.3.2.2. Formication
        • 7.3.2.3. Migraine
        • 7.3.2.4. Fatigue
        • 7.3.2.5. Anxiety
        • 7.3.2.6. Irritability
        • 7.3.2.7. Mood Swings
        • 7.3.2.8. Others
      • 7.3.3. Global Menopause Drugs Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Menopause Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Menopause Drugs: by End-users(USD Million)
  • Table 2. Menopause Drugs Hospitals & Clinics , by Region USD Million (2018-2023)
  • Table 3. Menopause Drugs Academia & Research , by Region USD Million (2018-2023)
  • Table 4. Menopause Drugs: by Symptoms(USD Million)
  • Table 5. Menopause Drugs Hot flashes , by Region USD Million (2018-2023)
  • Table 6. Menopause Drugs Formication , by Region USD Million (2018-2023)
  • Table 7. Menopause Drugs Migraine , by Region USD Million (2018-2023)
  • Table 8. Menopause Drugs Fatigue , by Region USD Million (2018-2023)
  • Table 9. Menopause Drugs Anxiety , by Region USD Million (2018-2023)
  • Table 10. Menopause Drugs Irritability , by Region USD Million (2018-2023)
  • Table 11. Menopause Drugs Mood Swings , by Region USD Million (2018-2023)
  • Table 12. Menopause Drugs Others , by Region USD Million (2018-2023)
  • Table 13. South America Menopause Drugs, by Country USD Million (2018-2023)
  • Table 14. South America Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 15. South America Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 16. South America Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 17. Brazil Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 18. Brazil Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 19. Brazil Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 20. Argentina Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 21. Argentina Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 22. Argentina Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 23. Rest of South America Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 24. Rest of South America Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 25. Rest of South America Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 26. Asia Pacific Menopause Drugs, by Country USD Million (2018-2023)
  • Table 27. Asia Pacific Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 28. Asia Pacific Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 29. Asia Pacific Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 30. China Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 31. China Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 32. China Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 33. Japan Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 34. Japan Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 35. Japan Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 36. India Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 37. India Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 38. India Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 39. South Korea Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 40. South Korea Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 41. South Korea Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 42. Taiwan Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 43. Taiwan Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 44. Taiwan Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 45. Australia Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 46. Australia Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 47. Australia Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 51. Europe Menopause Drugs, by Country USD Million (2018-2023)
  • Table 52. Europe Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 53. Europe Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 54. Europe Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 55. Germany Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 56. Germany Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 57. Germany Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 58. France Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 59. France Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 60. France Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 61. Italy Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 62. Italy Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 63. Italy Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 64. United Kingdom Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 65. United Kingdom Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 66. United Kingdom Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 67. Netherlands Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 68. Netherlands Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 69. Netherlands Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 70. Rest of Europe Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 71. Rest of Europe Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 72. Rest of Europe Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 73. MEA Menopause Drugs, by Country USD Million (2018-2023)
  • Table 74. MEA Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 75. MEA Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 76. MEA Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 77. Middle East Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 78. Middle East Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 79. Middle East Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 80. Africa Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 81. Africa Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 82. Africa Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 83. North America Menopause Drugs, by Country USD Million (2018-2023)
  • Table 84. North America Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 85. North America Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 86. North America Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 87. United States Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 88. United States Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 89. United States Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 90. Canada Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 91. Canada Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 92. Canada Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 93. Mexico Menopause Drugs, by End-users USD Million (2018-2023)
  • Table 94. Mexico Menopause Drugs, by Symptoms USD Million (2018-2023)
  • Table 95. Mexico Menopause Drugs, by Treatment USD Million (2018-2023)
  • Table 96. Menopause Drugs Sales: by End-users(K Units)
  • Table 97. Menopause Drugs Sales Hospitals & Clinics , by Region K Units (2018-2023)
  • Table 98. Menopause Drugs Sales Academia & Research , by Region K Units (2018-2023)
  • Table 99. Menopause Drugs Sales: by Symptoms(K Units)
  • Table 100. Menopause Drugs Sales Hot flashes , by Region K Units (2018-2023)
  • Table 101. Menopause Drugs Sales Formication , by Region K Units (2018-2023)
  • Table 102. Menopause Drugs Sales Migraine , by Region K Units (2018-2023)
  • Table 103. Menopause Drugs Sales Fatigue , by Region K Units (2018-2023)
  • Table 104. Menopause Drugs Sales Anxiety , by Region K Units (2018-2023)
  • Table 105. Menopause Drugs Sales Irritability , by Region K Units (2018-2023)
  • Table 106. Menopause Drugs Sales Mood Swings , by Region K Units (2018-2023)
  • Table 107. Menopause Drugs Sales Others , by Region K Units (2018-2023)
  • Table 108. South America Menopause Drugs Sales, by Country K Units (2018-2023)
  • Table 109. South America Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 110. South America Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 111. South America Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 112. Brazil Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 113. Brazil Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 114. Brazil Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 115. Argentina Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 116. Argentina Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 117. Argentina Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 118. Rest of South America Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 119. Rest of South America Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 120. Rest of South America Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 121. Asia Pacific Menopause Drugs Sales, by Country K Units (2018-2023)
  • Table 122. Asia Pacific Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 123. Asia Pacific Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 124. Asia Pacific Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 125. China Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 126. China Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 127. China Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 128. Japan Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 129. Japan Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 130. Japan Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 131. India Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 132. India Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 133. India Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 134. South Korea Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 135. South Korea Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 136. South Korea Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 137. Taiwan Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 138. Taiwan Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 139. Taiwan Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 140. Australia Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 141. Australia Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 142. Australia Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 143. Rest of Asia-Pacific Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 144. Rest of Asia-Pacific Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 145. Rest of Asia-Pacific Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 146. Europe Menopause Drugs Sales, by Country K Units (2018-2023)
  • Table 147. Europe Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 148. Europe Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 149. Europe Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 150. Germany Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 151. Germany Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 152. Germany Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 153. France Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 154. France Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 155. France Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 156. Italy Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 157. Italy Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 158. Italy Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 159. United Kingdom Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 160. United Kingdom Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 161. United Kingdom Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 162. Netherlands Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 163. Netherlands Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 164. Netherlands Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 165. Rest of Europe Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 166. Rest of Europe Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 167. Rest of Europe Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 168. MEA Menopause Drugs Sales, by Country K Units (2018-2023)
  • Table 169. MEA Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 170. MEA Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 171. MEA Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 172. Middle East Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 173. Middle East Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 174. Middle East Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 175. Africa Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 176. Africa Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 177. Africa Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 178. North America Menopause Drugs Sales, by Country K Units (2018-2023)
  • Table 179. North America Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 180. North America Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 181. North America Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 182. United States Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 183. United States Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 184. United States Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 185. Canada Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 186. Canada Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 187. Canada Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 188. Mexico Menopause Drugs Sales, by End-users K Units (2018-2023)
  • Table 189. Mexico Menopause Drugs Sales, by Symptoms K Units (2018-2023)
  • Table 190. Mexico Menopause Drugs Sales, by Treatment K Units (2018-2023)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Menopause Drugs: by End-users(USD Million)
  • Table 200. Menopause Drugs Hospitals & Clinics , by Region USD Million (2025-2030)
  • Table 201. Menopause Drugs Academia & Research , by Region USD Million (2025-2030)
  • Table 202. Menopause Drugs: by Symptoms(USD Million)
  • Table 203. Menopause Drugs Hot flashes , by Region USD Million (2025-2030)
  • Table 204. Menopause Drugs Formication , by Region USD Million (2025-2030)
  • Table 205. Menopause Drugs Migraine , by Region USD Million (2025-2030)
  • Table 206. Menopause Drugs Fatigue , by Region USD Million (2025-2030)
  • Table 207. Menopause Drugs Anxiety , by Region USD Million (2025-2030)
  • Table 208. Menopause Drugs Irritability , by Region USD Million (2025-2030)
  • Table 209. Menopause Drugs Mood Swings , by Region USD Million (2025-2030)
  • Table 210. Menopause Drugs Others , by Region USD Million (2025-2030)
  • Table 211. South America Menopause Drugs, by Country USD Million (2025-2030)
  • Table 212. South America Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 213. South America Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 214. South America Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 215. Brazil Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 216. Brazil Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 217. Brazil Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 218. Argentina Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 219. Argentina Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 220. Argentina Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 221. Rest of South America Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 222. Rest of South America Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 223. Rest of South America Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 224. Asia Pacific Menopause Drugs, by Country USD Million (2025-2030)
  • Table 225. Asia Pacific Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 226. Asia Pacific Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 227. Asia Pacific Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 228. China Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 229. China Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 230. China Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 231. Japan Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 232. Japan Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 233. Japan Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 234. India Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 235. India Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 236. India Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 237. South Korea Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 238. South Korea Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 239. South Korea Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 240. Taiwan Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 241. Taiwan Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 242. Taiwan Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 243. Australia Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 244. Australia Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 245. Australia Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 246. Rest of Asia-Pacific Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 247. Rest of Asia-Pacific Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 248. Rest of Asia-Pacific Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 249. Europe Menopause Drugs, by Country USD Million (2025-2030)
  • Table 250. Europe Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 251. Europe Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 252. Europe Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 253. Germany Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 254. Germany Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 255. Germany Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 256. France Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 257. France Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 258. France Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 259. Italy Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 260. Italy Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 261. Italy Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 262. United Kingdom Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 263. United Kingdom Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 264. United Kingdom Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 265. Netherlands Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 266. Netherlands Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 267. Netherlands Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 268. Rest of Europe Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 269. Rest of Europe Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 270. Rest of Europe Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 271. MEA Menopause Drugs, by Country USD Million (2025-2030)
  • Table 272. MEA Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 273. MEA Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 274. MEA Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 275. Middle East Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 276. Middle East Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 277. Middle East Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 278. Africa Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 279. Africa Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 280. Africa Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 281. North America Menopause Drugs, by Country USD Million (2025-2030)
  • Table 282. North America Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 283. North America Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 284. North America Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 285. United States Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 286. United States Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 287. United States Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 288. Canada Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 289. Canada Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 290. Canada Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 291. Mexico Menopause Drugs, by End-users USD Million (2025-2030)
  • Table 292. Mexico Menopause Drugs, by Symptoms USD Million (2025-2030)
  • Table 293. Mexico Menopause Drugs, by Treatment USD Million (2025-2030)
  • Table 294. Menopause Drugs Sales: by End-users(K Units)
  • Table 295. Menopause Drugs Sales Hospitals & Clinics , by Region K Units (2025-2030)
  • Table 296. Menopause Drugs Sales Academia & Research , by Region K Units (2025-2030)
  • Table 297. Menopause Drugs Sales: by Symptoms(K Units)
  • Table 298. Menopause Drugs Sales Hot flashes , by Region K Units (2025-2030)
  • Table 299. Menopause Drugs Sales Formication , by Region K Units (2025-2030)
  • Table 300. Menopause Drugs Sales Migraine , by Region K Units (2025-2030)
  • Table 301. Menopause Drugs Sales Fatigue , by Region K Units (2025-2030)
  • Table 302. Menopause Drugs Sales Anxiety , by Region K Units (2025-2030)
  • Table 303. Menopause Drugs Sales Irritability , by Region K Units (2025-2030)
  • Table 304. Menopause Drugs Sales Mood Swings , by Region K Units (2025-2030)
  • Table 305. Menopause Drugs Sales Others , by Region K Units (2025-2030)
  • Table 306. South America Menopause Drugs Sales, by Country K Units (2025-2030)
  • Table 307. South America Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 308. South America Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 309. South America Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 310. Brazil Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 311. Brazil Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 312. Brazil Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 313. Argentina Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 314. Argentina Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 315. Argentina Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 316. Rest of South America Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 317. Rest of South America Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 318. Rest of South America Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 319. Asia Pacific Menopause Drugs Sales, by Country K Units (2025-2030)
  • Table 320. Asia Pacific Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 321. Asia Pacific Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 322. Asia Pacific Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 323. China Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 324. China Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 325. China Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 326. Japan Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 327. Japan Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 328. Japan Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 329. India Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 330. India Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 331. India Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 332. South Korea Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 333. South Korea Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 334. South Korea Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 335. Taiwan Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 336. Taiwan Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 337. Taiwan Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 338. Australia Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 339. Australia Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 340. Australia Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 341. Rest of Asia-Pacific Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 342. Rest of Asia-Pacific Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 343. Rest of Asia-Pacific Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 344. Europe Menopause Drugs Sales, by Country K Units (2025-2030)
  • Table 345. Europe Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 346. Europe Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 347. Europe Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 348. Germany Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 349. Germany Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 350. Germany Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 351. France Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 352. France Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 353. France Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 354. Italy Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 355. Italy Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 356. Italy Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 357. United Kingdom Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 358. United Kingdom Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 359. United Kingdom Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 360. Netherlands Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 361. Netherlands Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 362. Netherlands Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 363. Rest of Europe Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 364. Rest of Europe Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 365. Rest of Europe Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 366. MEA Menopause Drugs Sales, by Country K Units (2025-2030)
  • Table 367. MEA Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 368. MEA Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 369. MEA Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 370. Middle East Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 371. Middle East Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 372. Middle East Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 373. Africa Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 374. Africa Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 375. Africa Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 376. North America Menopause Drugs Sales, by Country K Units (2025-2030)
  • Table 377. North America Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 378. North America Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 379. North America Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 380. United States Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 381. United States Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 382. United States Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 383. Canada Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 384. Canada Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 385. Canada Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 386. Mexico Menopause Drugs Sales, by End-users K Units (2025-2030)
  • Table 387. Mexico Menopause Drugs Sales, by Symptoms K Units (2025-2030)
  • Table 388. Mexico Menopause Drugs Sales, by Treatment K Units (2025-2030)
  • Table 389. Research Programs/Design for This Report
  • Table 390. Key Data Information from Secondary Sources
  • Table 391. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Menopause Drugs: by End-users USD Million (2018-2023)
  • Figure 5. Global Menopause Drugs: by Symptoms USD Million (2018-2023)
  • Figure 6. South America Menopause Drugs Share (%), by Country
  • Figure 7. Asia Pacific Menopause Drugs Share (%), by Country
  • Figure 8. Europe Menopause Drugs Share (%), by Country
  • Figure 9. MEA Menopause Drugs Share (%), by Country
  • Figure 10. North America Menopause Drugs Share (%), by Country
  • Figure 11. Global Menopause Drugs: by End-users K Units (2018-2023)
  • Figure 12. Global Menopause Drugs: by Symptoms K Units (2018-2023)
  • Figure 13. South America Menopause Drugs Share (%), by Country
  • Figure 14. Asia Pacific Menopause Drugs Share (%), by Country
  • Figure 15. Europe Menopause Drugs Share (%), by Country
  • Figure 16. MEA Menopause Drugs Share (%), by Country
  • Figure 17. North America Menopause Drugs Share (%), by Country
  • Figure 18. Global Menopause Drugs share by Players 2023 (%)
  • Figure 19. Global Menopause Drugs share by Players (Top 3) 2023(%)
  • Figure 20. Global Menopause Drugs share by Players (Top 5) 2023(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 23. Novo Nordisk A/S (Denmark) Revenue: by Geography 2023
  • Figure 24. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 27. Allergan (Ireland) Revenue: by Geography 2023
  • Figure 28. Eli Lily and Company (United States) Revenue, Net Income and Gross profit
  • Figure 29. Eli Lily and Company (United States) Revenue: by Geography 2023
  • Figure 30. Emcure Pharmaceuticals Ltd (India) Revenue, Net Income and Gross profit
  • Figure 31. Emcure Pharmaceuticals Ltd (India) Revenue: by Geography 2023
  • Figure 32. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 34. Cipla Inc. (India) Revenue, Net Income and Gross profit
  • Figure 35. Cipla Inc. (India) Revenue: by Geography 2023
  • Figure 36. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 37. Teva Pharmaceuticals (Israel) Revenue: by Geography 2023
  • Figure 38. Global Menopause Drugs: by End-users USD Million (2025-2030)
  • Figure 39. Global Menopause Drugs: by Symptoms USD Million (2025-2030)
  • Figure 40. South America Menopause Drugs Share (%), by Country
  • Figure 41. Asia Pacific Menopause Drugs Share (%), by Country
  • Figure 42. Europe Menopause Drugs Share (%), by Country
  • Figure 43. MEA Menopause Drugs Share (%), by Country
  • Figure 44. North America Menopause Drugs Share (%), by Country
  • Figure 45. Global Menopause Drugs: by End-users K Units (2025-2030)
  • Figure 46. Global Menopause Drugs: by Symptoms K Units (2025-2030)
  • Figure 47. South America Menopause Drugs Share (%), by Country
  • Figure 48. Asia Pacific Menopause Drugs Share (%), by Country
  • Figure 49. Europe Menopause Drugs Share (%), by Country
  • Figure 50. MEA Menopause Drugs Share (%), by Country
  • Figure 51. North America Menopause Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novo Nordisk A/S (Denmark)
  • Pfizer Inc. (United States)
  • Allergan (Ireland)
  • Eli Lily and Company (United States)
  • Emcure Pharmaceuticals Ltd (India)
  • Novartis AG (Switzerland)
  • Cipla Inc. (India)
  • Teva Pharmaceuticals (Israel)
Additional players considered in the study are as follows:
Merck & Co. Inc. (United States) , Abbott Laboratories (United States) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 203 Pages 72 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Menopause Drugs Market Quantitative research analysis
Global Menopause Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novo Nordisk A/S (Denmark), Pfizer Inc. (United States), Allergan (Ireland), Eli Lily and Company (United States), Emcure Pharmaceuticals Ltd (India), Novartis AG (Switzerland), Cipla Inc. (India) and Teva Pharmaceuticals (Israel) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Investments are being made in Extensive R&D activities to Launch Novel Drugs, which helps bolster the Menopause Treatment" is seen as one of major influencing trends for Menopause Drugs Market during projected period 2023-2030.
The Menopause Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Menopause Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Emphysema Drug- Comprehensive Study by Drugs (Aclidinium Bromide Oral Inhalation, Albuterol and Ipratropium, Alpha One-proteinase inhibitor, Indacaterol, Others), Therapy (Pulmonary Rehabilitation, N...
$ 3750
Tenosynovitis Drugs Comprehensive Study by Product type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Antibiotics, Corticosteroids), End user (Hospitals, Drugstores, Others) Players and Region - Gl...
$ 3500
Malnutrition_ Comprehensive Study by Type (Under Nutrition, Over Nutrition), Treatment (Intravenously (Par-enteral Nutrition), Gastrointestinal Tract (Enteral Nutrition)), Causes (A Low Intake Of Foo...
$ 3800
Immune Cell Therapy Comprehensive Study by Application (Cancer, Autoimmune Disease, Chronic Inflammation), Forms (Nonspecific Immunotherapies, Cancer Vaccines), End User (Hospitals, Cancer Research C...
$ 3400
Oxycodone Drug Comprehensive Study by Distribution Channel (Online {Company Website, E-Commerce Website}, Offline {Pharma Stores, Local Medical Stores}), End Use (Hospitals, Clinics, Diagnostic Cente...
$ 3800
Spiramycin Drug Comprehensive Study by Type (Oral route {Capsule, Tablets}, Rectal route {Suppository}, Injection route), Disease (Toxoplasmosis, Cryptosporidiosis), Distribution Channel (Hospital ph...
$ 3800